SREBF2 and melanoma: Therefore, this result (Figure 4) is medically relevant, and targeting SREBP2-driven mevalonate pathway upregulation may offer a new avenue for treating melanomas resistant to vemurafenib or to potentiate the effect of vemurafenib.